Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia (AML).
Read the full article on WikipediaAcute Myeloid Leukaemia Clinical criteria: Treatment Phase: Induction treatment Patient must have confirmed CD33-positive AML prior to initiation of treatment, AND The condition must be de novo, AND The condition must be previously untreated at the time of initiation (except for prior essential treatment with hydroxyurea or leukapheresis for patients with hyperleukocytic AML), AND Patient must have confirmed intermediate/favourable cytogenetic risk; OR Patient must have unknown cytogenetic risk due to inconclusive test results, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, AND The condition must not be acute promyelocytic leukaemia, AND The treatment must be in combination with standard intensive remission induction chemotherapy for this condition, which must include cytarabine and an anthracycline, AND The treatment must not be used in combination with a tyrosine kinase inhibitor, AND The condition must not be internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive, AND Patient must not receive more than 1 induction cycle under this restriction in a lifetime. This drug is not PBS-subsidised if it is prescribed to an in-patient in a public hospital setting.
“Gemtuzumab ozogamicin is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ antibody hP67.6) covalently attached to the cytotoxic antitumor antibiotic calicheamicin (N-acetyl-γ-calicheamicin) payload via a bifunctional linker (4-(4-acetylphenoxy)butanoic acid).”
Working under the parallel aged-care framework? Aged-care equivalent →